- Trial phase
- Phase 1 completed / Phase 2 ongoing
- Time to market
- If Phase 2 and Phase 3 trials are successful, a potential approval would likely be 4-6 years away, though Vertex could potentially leverage its established CF regulatory pathway to accelerate development.
- Why 3/10
- VX-828 has no hard-dated binary catalyst in the next ~12 months; the Phase 2 proof-of-concept readout is a soft 'H2 2026' target with no specific date, and as an early-stage drug at a large, diversified biotech it is not the primary value driver for VRTX.
The Phase 2 proof-of-concept readout for VX-828 is expected by late 2026 but has no hard date. Positive data showing lung function improvement in the F/MF genotype would validate Vertex's next-generation CFTR corrector platform but is unlikely to move VRTX materially given the stock is driven by the povetacicept PDUFA (Nov 30, 2026), suzetrigine launch, and the broad CF franchise.
Price Chart
Executive Summary
VX-828 is Vertex Pharmaceuticals' first 'next-generation 3.0' CFTR corrector, an oral small molecule for cystic fibrosis. A Phase 1 first-in-human study (NCT06154447, 165 participants) completed in July 2026, and Vertex announced today (Q3 2026 earnings) that the triple combination containing VX-828 was 'safe and well tolerated' in people with CF. A Phase 2 proof-of-concept study (VX25-828-101, ~152 adults) received a favorable UK ethics opinion in June 2026, with results guided for H2 2026. As an early-stage asset at a large-cap biotech with multiple marketed CF drugs, VX-828 is not a primary VRTX share-price driver.
How It Works
VX-828 is an oral small molecule that belongs to a new generation ('3.0') of CFTR correctors. Cystic fibrosis is caused by a faulty CFTR protein, which cannot properly move salt and water across cell membranes, leading to thick mucus in the lungs and other organs. VX-828 helps correct the shape of the defective CFTR protein so it can function more normally, and is designed to be used in a triple combination with other CFTR modulators (tezacaftor and deutivacaftor).
Trial Status
Phase 1 first-in-human study (NCT06154447) completed July 10, 2026, showing safety and tolerability of VX-828 in triple combination in people with CF. A Phase 1 tablet bioavailability study (NCT06861413) also completed. A Phase 2 randomized, double-blind, controlled study (VX25-828-101) evaluating VX-828/deutivacaftor with/without tezacaftor in ~152 adults with CF is ongoing with proof-of-concept results expected in H2 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 proof-of-concept topline results (soft target: H2 2026; no specific date announced)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report